Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics (NASDAQ:NTLA) has announced an inducement grant award to a new employee under its 2024 Inducement Plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Intellia Therapeutics (NASDAQ:NTLA) has announced an inducement grant award to a new employee under its 2024 Inducement Plan. The grant consists of 3,521 restricted stock units (RSUs) of Intellia's common stock, which will vest in three equal installments on December 1 of 2025, 2026, and 2027. The award was granted outside of Intellia's stockholder-approved equity incentive plans and was approved by the company's compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Details
News Market Reaction – NTLA
The recorded move for NTLA in the trading session of this news was -1.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on December 1, 2024, it awarded an inducement grant to one new employee under Intellia’s 2024 Inducement Plan as a material inducement to employment.
The inducement grant consisted of time-based restricted stock units (“RSUs”) for 3,521 shares of Intellia’s common stock, with one-third of such RSUs vesting on December 1, 2025, 2026, and 2027.
All equity vesting is subject to the employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
The above-described award was granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. The award was approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company’s in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia’s ex vivo programs use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Lina Li
Senior Director, Investor Relations and Corporate Communications
lina.li@intelliatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.